Bybit Restarts UK Spot Trading Under FCA-Aligned Framework
Bybit has resumed spot trading for UK users after a months‑long pause, reintroducing roughly 100 spot pairs and P2P services while keeping derivatives and certain products restricted. The relaunch follows continued dialogue with the UK Financial Conduct Authority (FCA) and uses an FCA‑aligned arrangement — with authorised firm Archax approving Bybit’s financial promotions in the UK — to meet local financial promotion standards. Bybit says it has strengthened KYC, AML and transaction monitoring and will roll out additional UK‑tailored products gradually. The move reflects growing UK crypto adoption and ongoing UK regulatory work (with new rules targeted by 2027). For traders: renewed access to Bybit’s spot liquidity in the UK may change local order flow, tighten or widen spreads depending on flows, and affect short‑term price dynamics for major tokens. Compliance‑focused marketing via an FCA‑authorised approver reduces legal risk for outreach to UK retail, but the evolving regulatory regime could alter product availability and compliance costs over time.
Neutral
Reintroducing Bybit spot trading in the UK is a neutral-to-mildly bullish event for spot market liquidity but not clearly bullish for prices. Short-term impact: liquidity returning to a major offshore venue can tighten spreads and increase order book depth for listed tokens, potentially reducing short-term volatility for some pairs while generating transient price moves as flows reallocate. Derivatives remain restricted, limiting leverage-driven directional pressure that often amplifies bullish or bearish moves. Medium-to-long term: compliance alignment with an FCA‑authorised approver reduces regulatory tail risk for UK retail access, which may sustainably grow local order flow; however, pending UK rule changes (target 2027) and possible future restrictions could increase compliance costs or product limitations, capping a clear bullish case. Overall, the net effect is increased market access and liquidity but with mixed price-directional implications due to remaining product limits and regulatory uncertainty.